Op-ed: 5 un­set­tled is­sues a Califf-run FDA will need to tack­le in 2022 and be­yond

As Rob Califf like­ly makes his re­turn as FDA com­mis­sion­er next month, his con­fir­ma­tion hear­ing yes­ter­day of­fered a peek in­to some of the larg­er ob­sta­cles …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER